You have 9 free searches left this month | for more free features.

Squamous Cell Lung Cancer

Showing 1 - 25 of >10,000

STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS

Lung Cancer Trial (Cadonilimab)

Not yet recruiting
  • Lung Cancer
  • (no location specified)
Mar 23, 2023

Advanced Lung Squamous Cell Carcinoma Trial in Chengdu (low-dose radiation therapy and stereotactic body radiation therapy,

Not yet recruiting
  • Advanced Lung Squamous Cell Carcinoma
  • low-dose radiation therapy and stereotactic body radiation therapy
  • +2 more
  • Chengdu, Sichuan, China
    West China Hospital of Sichuan University
Nov 13, 2023

Lung Cancer Trial in Tampa, Columbus (Carboplatin, Paclitaxel, AZD1775)

Active, not recruiting
  • Lung Cancer
  • Tampa, Florida
  • +1 more
Feb 2, 2023

NSCLC, Squamous Cell Carcinoma Trial in Wuhan (Nab-paclitaxel, Carboplatin, Thoracic radiation therapy)

Terminated
  • Carcinoma, Non-Small-Cell Lung
  • Squamous Cell Carcinoma
  • Wuhan, Hubei, China
    Zhongnan Hospital of Wuhan University
Apr 26, 2022

Squamous Cell Lung Cancer Trial in United States (ZEN003694)

Recruiting
  • Squamous Cell Lung Cancer
  • Basking Ridge, New Jersey
  • +6 more
Nov 1, 2022

Advanced Squamous Non Small Cell Lung Cancer Trial (AK112, Carboplatin, Paxlitaxel, Tislelizumab, Carboplatin, Paxlitaxel)

Not yet recruiting
  • Advanced Squamous Non Small Cell Lung Cancer
  • AK112, Carboplatin, Paxlitaxel
  • Tislelizumab, Carboplatin, Paxlitaxel
  • (no location specified)
Apr 21, 2023

NSCLC, Metastatic Non Small Cell Lung Cancer, Stage IV NSCLC Trial in Duarte, Minneapolis (Fludarabine, Cyclophosphamide, CISH

Not yet recruiting
  • Carcinoma, Non-Small-Cell Lung
  • +5 more
  • Duarte, California
  • +1 more
Dec 7, 2022

Advanced Squamous Non-Small-Cell Lung Cancer Trial (Trilaciclib, Carboplatin, Paclitaxel)

Not yet recruiting
  • Advanced Squamous Non-Small-Cell Lung Cancer
  • (no location specified)
Jun 11, 2023

Squamous Cell Lung Cancer, Vulvar Cancer, Penile Cancer Trial in France (pembrolizumab; vorinostat)

Active, not recruiting
  • Squamous Cell Lung Cancer
  • +5 more
  • pembrolizumab; vorinostat
  • Angers, France
  • +13 more
Jan 4, 2023

Sinonasal Cancer, Squamous NSCLC, Lung Cancer Trial run by the National Cancer Institute (NCI) (pembrolizumab, valemetostat)

Not yet recruiting
  • Sinonasal Cancer
  • +5 more
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Jun 5, 2023

Exhaled Breath Particles in Lung Cancer

Recruiting
  • Lung Cancer
  • +3 more
  • EBPcollected using the PExA device.
  • Lund, Skåne Län, Sweden
    Skåne University Hospital
May 24, 2022

Non Squamous Non Small Cell Lung Cancer, EGFR Positive NSCLC Trial (Toripalimab plus Chemotherapy)

Not yet recruiting
  • Non Squamous Non Small Cell Lung Cancer
  • EGFR Positive Non-small Cell Lung Cancer
  • Toripalimab plus Chemotherapy
  • (no location specified)
Jul 28, 2023

NSCLC Trial (Ivonescimab Injection, Pembrolizumab Injection)

Not yet recruiting
  • Non-Small Cell Lung Cancer
  • Ivonescimab Injection
  • Pembrolizumab Injection
  • (no location specified)
Jun 9, 2023

NSCLC Trial in Wuhan (Cadonilimab, Pemetrexed, Carboplatin)

Recruiting
  • Carcinoma, Non-Small-Cell Lung
  • Wuhan, Hubei, China
    Qian Chu
Aug 18, 2023

PARP Inhibitor for Esophageal Squamous Cell Carcinoma Trial (Fluzoparib monotherapy or Fluzoparib with Camrelizumab(Only

Not yet recruiting
  • PARP Inhibitor for Esophageal Squamous Cell Carcinoma
  • Fluzoparib monotherapy or Fluzoparib with Camrelizumab(Only non-small cell lung cancer arm) ,or Fluzoparib combined with capecitabine (only rectal cancer arm))
  • (no location specified)
Sep 24, 2023

Progression of Invasive Squamous Cell Carcinoma

Recruiting
  • Carcinoma, Squamous Cell
  • +10 more
  • DNA Extraction
  • Rochester, Minnesota
    Mayo Clinic in Rochester
Sep 27, 2022

Advanced or Metastatic Squamous NSCLC Trial in Sydney (HMBD-001, Docetaxel, Cetuximab)

Not yet recruiting
  • Advanced or Metastatic Squamous Non-Small Cell Lung Cancer
  • Sydney, New South Wales, Australia
    GenesisCare North Shore
Jun 20, 2023

NSCLC Trial in Chongqing (procedure, drug, radiation)

Not yet recruiting
  • Carcinoma, Non-Small-Cell Lung
  • bronchial artery interventional therapy
  • +3 more
  • Chongqing, Chongqing, China
    Daping Hospital, Third Military Medical University
May 27, 2023

Non-small Cell Lung Adenocarcinoma, Squamous Cell Carcinoma of Lung Trial in Guangzhou (SI-B001, Docetaxel)

Not yet recruiting
  • Non-small Cell Lung Adenocarcinoma
  • Squamous Cell Carcinoma of Lung
  • Guangzhou, Guangdong, China
    Sun Yat-sen University Cancer Center
Jul 5, 2023

NSCLC Trial in Wuhan (Adebrelimab Combined With Bevacizumab and Albumin Paclitaxel)

Recruiting
  • Non-small Cell Lung Cancer
  • Adebrelimab Combined With Bevacizumab and Albumin Paclitaxel
  • Wuhan, Hubei, China
    Union hospital
Feb 20, 2023

NSCLC Trial in Pittsburgh (M1774, Cemiplimab)

Not yet recruiting
  • Non-Small Cell Lung Cancer
  • Pittsburgh, Pennsylvania
    UPMC Cancer Center
May 22, 2023

NSCLC Trial in Pittsburgh (Tiragolumab, Atezolizumab, Pemetrexed)

Not yet recruiting
  • Non-small Cell Lung Cancer
  • Pittsburgh, Pennsylvania
    UPMC Hillman Cancer Center
Feb 16, 2023

Recurrent Squamous Cell Lung Carcinoma, Stage IV Squamous Cell Lung Carcinoma AJCC V7 Trial in Houston (ABBV-399)

Completed
  • Recurrent Squamous Cell Lung Carcinoma
  • Stage IV Squamous Cell Lung Carcinoma AJCC V7
  • Houston, Texas
    M D Anderson Cancer Center
Sep 21, 2021

Non-Squamous NSCLC (NSCLC), Adenocarcinoma of the Lung, Lung Cancer Trial in United States (Docetaxel, Nivolumab, Gemcitabine)

Terminated
  • Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
  • +3 more
  • Anderson, Indiana
  • +8 more
Jul 7, 2022

Subjects Treated With Autologous T Cells Using Sleeping Beauty

Not yet recruiting
  • Gynecologic Cancer
  • +9 more
  • Neoantigen specific TCR-T cell drug product
  • Houston, Texas
    MD Anderson Cancer Center
Jul 27, 2022